Polymorphisms identified at baseline
| Variant . | Nucleotide change . | Codon . | All patients (N = 846), n (%) . | Nilotinib 300 mg twice daily (n = 282), n . | Nilotinib 400 mg twice daily (n = 281), n . | Imatinib 400 mg once daily (n = 283), n . |
|---|---|---|---|---|---|---|
| T83T | ACT→ACG | c.252T→G | 1 (0.1) | 0 | 1 | 0 |
| N96S | AAT→AGT | c.290A→G | 1 (0.1) | 0 | 1 | 0 |
| T117T | ACG→ACA | c.344G→A | 1 (0.1) | 0 | 0 | 1 |
| T204T | ACG→ACA | c.615G→A | 1 (0.1) | 1 | 0 | 0 |
| T240T* | ACG→ACA | c.723G→A | 2 (0.2) | 1 | 1 | 0 |
| Y253Y | TAC→TAT | c.762C→T | 1 (0.1) | 0 | 0 | 1 |
| E499E* | GAA→GAG | c.1500A→G | 53 (6.3) | 21 | 17 | 15 |
| Variant . | Nucleotide change . | Codon . | All patients (N = 846), n (%) . | Nilotinib 300 mg twice daily (n = 282), n . | Nilotinib 400 mg twice daily (n = 281), n . | Imatinib 400 mg once daily (n = 283), n . |
|---|---|---|---|---|---|---|
| T83T | ACT→ACG | c.252T→G | 1 (0.1) | 0 | 1 | 0 |
| N96S | AAT→AGT | c.290A→G | 1 (0.1) | 0 | 1 | 0 |
| T117T | ACG→ACA | c.344G→A | 1 (0.1) | 0 | 0 | 1 |
| T204T | ACG→ACA | c.615G→A | 1 (0.1) | 1 | 0 | 0 |
| T240T* | ACG→ACA | c.723G→A | 2 (0.2) | 1 | 1 | 0 |
| Y253Y | TAC→TAT | c.762C→T | 1 (0.1) | 0 | 0 | 1 |
| E499E* | GAA→GAG | c.1500A→G | 53 (6.3) | 21 | 17 | 15 |
All sequence variants were verified to be present in nontranslocated ABL; therefore, they are polymorphisms.
T240T and E499E are previously reported polymorphisms.